Business
Solvonis Chair to speak at Lucid Capital Markets
Solvonis Chair to speak at Lucid Capital Markets.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\n14 July 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nSolvonis Chair Dennis Purcell to speak at Lucid Capital Markets biotech leadership event.\n \nSolvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders is pleased to announce that its Chairman, Dennis Purcell, will participate in an exclusive investor event hosted by Lucid Capital Markets on Thursday, 17 July 2025 at 2:00pm ET.\nThe event, moderated by Elemér Piros, PhD, Managing Director and Senior Biotech Analyst at Lucid Capital Markets, features a panel discussion with three of the most influential figures in global biopharma: Dennis Purcell (Chair, Solvonis; Founder, Aisling Capital), Stelios Papadopoulos (Chair, Exelixis), and Jeremy Levin (Chair and CEO, Ovid Therapeutics).\nThe session will explore leadership, innovation, and strategic capital deployment across the biotechnology sector.\nDennis Purcell brings more than 30 years of experience in life sciences investment, having deployed over $15 billion in more than 200 companies through Aisling Capital. His participation in this panel underscores the strength of strategic leadership at Solvonis as the Company advances its AI-enabled CNS drug discovery platform.\nEvent details:\nDate: Thursday, 17 July 2025\nTime: 2:00pm ET / 7:00pm BST\nRegistration link: https://lnkd.in/eq5pWiFn\n \nEnquiries:\n\nSolvonis Therapeutics plc\nAnthony Tennyson, CEO & Executive Director\[email protected]\n\nAllenby Capital Limited (Financial Adviser and Joint Broker)\nNick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)\nGuy McDougall (Sales & Corporate Broking)\n+44 (0) 20 3328 5656\n\nSinger Capital Markets (Joint Broker)\nPhil Davies\n+44 (0) 20 7496 3000\n\nAbout Solvonis Therapeutics plc\nSolvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.\nThe Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-...